Skip to content
Quebec News Tribune – Lifestyle
Author:
Climb Bio, Inc.
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
November 4, 2026
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
November 2, 2026
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
October 24, 2026
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
October 23, 2026
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
October 2, 2026
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
September 3, 2026
Climb Bio to Present at Upcoming Investor Conferences
September 2, 2026
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
June 11, 2026
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
June 5, 2026
1
2
Next Page
→